Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
Years of dreams about CARs turn into reality for Atara
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
Oncocyte banks on a new kind of liquid biopsy
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Check-Cap auditions for its screen debut
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
Noxxon nears crucial combo readout
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
FDA decision time looms for Gelesis
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
GTX Medical must go from breakthrough to break-even
Technology developed by GTX Medical has shown astonishing results in paralysed patients. Monetising it might be an even more impressive achievement.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.